# Armoured, logic-gated & next-gen CARs

Source: https://onco.cc/technologies/armored-car/  
OnCo record `armored-car` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Upgraded CAR-T cells that also secrete immune boosters, resist exhaustion, or only fire when two signals are present.

## Summary

Armoured and logic-gated CARs add transgenes or synthetic circuits that change how CAR-T cells behave in the tumour microenvironment: IL-12 or IL-18 secretion, dominant-negative TGF-β receptors, PD-1 knockout, synNotch logic gates (AND/NOT gating for solid tumours, for example Arsenal Bio), and tunable CARs. Each design addresses one of the solid-tumour barriers of exhaustion, immune suppression, or on-target off-tumour toxicity, with logic gating meant to fire only when two antigens are present together. These constructs are designed for hostile solid-tumour environments where first-generation CARs failed. The cost is complexity, and the safety of constitutively secreted cytokines is unresolved, so most programmes are phase 1. The simple version is an upgraded CAR-T that carries its own boosters, armour, or a two-signal safety switch.

## Fields

- Kind: Technology
- Status: phase-1
- Last checked: 2026-09-04
- Tags: frontier
- Principle: Additional transgenes or synthetic circuits modify CAR-T behaviour in the tumour microenvironment.
- Strengths: Designed for hostile solid-tumour environments
- Limitations: Complexity, safety of constitutive cytokines

## Sources

- ClinicalTrials.gov NCT03373097: GD2-CART01 (Bambino Gesù phase 1/2): https://clinicaltrials.gov/study/NCT03373097

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T against stroma: fibroblasts and myeloid cells](https://onco.cc/technologies/stroma-directed-car/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)](https://onco.cc/technologies/glioma-car-t/), [Logic-gated therapeutics (AND, NOT gates)](https://onco.cc/technologies/logic-gated-therapeutics/)
- companies: [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/), [Modulari-T](https://onco.cc/companies/modulari-t/), [Tmunity Therapeutics](https://onco.cc/companies/tmunity-therapeutics/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- ideas: [Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer](https://onco.cc/ideas/idea-moon-engineered-immune-surveillance/), [GD2 CAR-T as consolidation in high-risk neuroblastoma](https://onco.cc/ideas/idea-gd2-car-t-frontline-consolidation/), [Regionally delivered mesothelin CAR-T with PD-1 blockade](https://onco.cc/ideas/idea-mesothelin-car-t-regional/)
- trials: [GD2-CART01 (Bambino Gesù phase 1/2)](https://onco.cc/trials/gd2-cart01/)
- roadmaps: [Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR](https://onco.cc/roadmaps/cell-therapy-roadmap/)
- people: [Christine E. Brown](https://onco.cc/people/christine-brown/), [Crystal L. Mackall](https://onco.cc/people/crystal-mackall/), [Marcela V. Maus](https://onco.cc/people/marcela-maus/), [Renier J. Brentjens](https://onco.cc/people/renier-brentjens/), [Robbie G. Majzner](https://onco.cc/people/robbie-majzner/)
- terms: [T-cell exhaustion and CAR-T persistence](https://onco.cc/terms/t-cell-exhaustion-term/)
- pathways: [Nutrient competition & metabolic immunosuppression](https://onco.cc/pathways/nutrient-competition-tme/), [T-cell exhaustion](https://onco.cc/pathways/t-cell-exhaustion/)

---
JSON: https://onco.cc/api/v1/entities/armored-car.json